Addax Biosciences S.r.l.
Activity description
ADDAX Biosciences has developed and commercializes GAF (glyoxal acid-free), a non-carcinogenic and non-volatile fixative, which stands as effective alternative to Formalin, a formaldehyde-based water solution, largely used since decades in the histological fixation field.
European Regulation (EU) n. 895/2014 recognized Formaldehyde as a carcinogenic substance, and prohibited its use, production, and commercialization from August 2017.
However, so far, there is no valid alternative to Formalin accepted by the scientific community and, consequently, thousands of workers are exposed to formaldehyde vapors.
GAF is a unique Formalin substitute, with comparable or better fixative capability. It allows an optimal fixation of the tissue at structural and molecular level, and, at the same time, it is non- carcinogenic nor volatile.
ADDAX Biosciences aims to achieve formalin-free hospitals and laboratories, producing a strong social impact by protecting health of the workers all around the world.
